Carboxy-PTIO, potassium salt |
| Catalog No.GC16211 |
Carboxy-PTIO, potassium salt은 일산화질소(NO) 청소부이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 148819-94-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Carboxy-PTIO, potassium salt은 일산화질소(NO) 청소부이다. Carboxy-PTIO, potassium salt은 NO와 계량 반응을하고 NO의 EPR 검출에 사용할 수 있다[2].
체외 실험에서 A375-S2 세포에 Carboxy-PTIO, potassium salt (200µM)을 1시간 동안 사전 처리하면 physalin A가 유도한 NO 표현을 현저하게 억제하고 procaspase-3 및 PARP의 분열을 줄이고 mTOR 및 p-mTOR 수준의 하강을 반전시키며 세포 내 LC3 I에서 LC3 II로의 전환도 억제한다[3]. HUVEC 세포에 Carboxy-PTIO, potassium salt (100µM)을 6시간 동안 사전 처리하면 IL-1β가 PGIS에 미치는 억제 효과를 현저하게 강화한다[4]. MDA-MB-231 세포에 Carboxy-PTIO, potassium salt (0.5µM, 1µM)을 1시간 동안 사전 처리하면 합성물 3a-f가 세포에 미치는 억제 활동을 현저하게 낮춘다[5].
체내 실험에서 뇌허혈성 손상을 가진 쥐에게 뇌졸중을 유발하는 Carboxy-PTIO, potassium salt (0.3-1.2 mg/kg)을 정맥 주입하면 치료가 최대 4시간 지연되었음에도 뇌졸중 발생률이 약물 농도에 따라 27%에서 30%까지 감소했다[6]. 내독성 충격을 가진 쥐에게 Carboxy-PTIO, potassium salt (0.056-1.70 mg/kg/min)을 60분 동안 정맥 주입하여 쥐의 저혈압과 신장 기능 부전 증상을 현저하게 개선하고 충격 상태를 피했다[7].
References:
[1]Pfeiffer S, Leopold E, Hemmens B, et al. Interference of carboxy-PTIO with nitric oxide-and peroxynitrite-mediated reactions[J]. Free Radical Biology and Medicine, 1997, 22(5): 787-794.
[2]T Akaike, et al. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry. 1993 Jan 26;32(3):827-32.
[3] He H, Feng Y S, Zang L H, et al. Nitric oxide induces apoptosis and autophagy; autophagy down-regulates NO synthesis in physalin A-treated A375-S2 human melanoma cells[J]. Food and chemical toxicology, 2014, 71: 128-135.
[4] Camacho M, LÓpez-Belmonte J, Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity[J]. Circulation research, 1998, 83(4): 353-365.
[5] Kang F, Zhu J, Wu J, et al. O 2-3-Aminopropyl diazeniumdiolates suppress the progression of highly metastatic triple-negative breast cancer by inhibition of microvesicle formation via nitric oxide-based epigenetic regulation[J]. Chemical Science, 2018, 9(34): 6893-6898.
[6]Lee E J, Hung Y C, Chen H Y, et al. Delayed treatment with carboxy-PTIO permits a 4-h therapeutic window of opportunity and prevents against ischemia-induced energy depletion following permanent focal cerebral ischemia in mice[J]. Neurochemical research, 2009, 34: 1157-1166.
[7]Yoshida M, Akaike T, Wada Y, et al. Therapeutic effects of imidazolineoxyl N-oxide against endotoxin shock through its direct nitric oxide-scavenging activity[J]. Biochemical and biophysical research communications, 1994, 202(2): 923-930.
| 세포 실험 [1]: | |
세포 라인 | A375-S2세포 |
제조 방법 | A375-S2 세포는 15µM의 physalin A 처리 24시간 전에 1400W(200µM)나 Carboxy-PTIO, potassium salt (200µM)으로 1시간 사전 처리를 받았습니다. |
반응 조건 | 200µM; 1 시간 동안 |
응용 분야 | 일산화질소 합성 효소 억제제인 1400W와 NO 스케이버거인 Carboxy-PTIO, potassium salt은 physalin A 처리로 인한 NO 표현의 자극을 현저하게 억제했습니다. |
| 동물 실험 [2]: | |
동물 모형 | C57BL/10J 쥐 |
제조 방법 | 동물은 MCA 폐색 시 Carboxy-PTIO, potassium salt (0.3-1.2 mg/kg; i.p.) 또는 동일량의 식염수를 투여받도록 배정되었습니다. 뇌 뇌혈액 유도 전과 후 45분 동안 동맥혈기, 혈당, 적혈구 농도 및 혈압을 측정하기 위해 우측 대퇴동맥에 캔늘을 삽입했습니다. |
제형 | 0.3-1.2 mg/kg；i.p. |
응용 분야 | Carboxy-PTIO, potassium salt을 치료받은 쥐는 뇌졸중 면적이 약물별 특이적으로 줄어들었고 27-30%까지 현저히 감소시켰습니다. 이는 치료가 뇌졸중 손상 후 최대 4시간 지연되었음에도 불구하고도 효과가 있었습니다. |
참고문헌: [1] He H, Feng Y S, Zang L H, et al. Nitric oxide induces apoptosis and autophagy; autophagy down-regulates NO synthesis in physalin A-treated A375-S2 human melanoma cells[J]. Food and chemical toxicology, 2014, 71: 128-135.[2] Lee E J, Hung Y C, Chen H Y, et al. Delayed treatment with carboxy-PTIO permits a 4-h therapeutic window of opportunity and prevents against ischemia-induced energy depletion following permanent focal cerebral ischemia in mice[J]. Neurochemical research, 2009, 34: 1157-1166. | |
| Cas No. | 148819-94-7 | SDF | |
| Chemical Name | 2-(4-carboxyphenyl)-4,5-dihydro-4,4,5,5-tetramethyl-1H-imidazolyl-1-oxy-3-oxide, monopotassium salt | ||
| Canonical SMILES | CC(C1(C)C)(N(=C(N1[O])C2=CC=C(C([O-])=O)C=C2)=O)C.[K+] | ||
| Formula | C14H16KN2O4 | M.Wt | 315.38 |
| Solubility | >1.4 mg/ml in DMSO, >3.3 mg/ml in DMF, >1.6mg/ml in Ethanol | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1708 mL | 15.8539 mL | 31.7078 mL |
| 5 mM | 0.6342 mL | 3.1708 mL | 6.3416 mL |
| 10 mM | 0.3171 mL | 1.5854 mL | 3.1708 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *